Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

• Status: Unknown status
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment.

Secondary Study Objectives

• To monitor adverse events and changes in hemoglobin and serum chemistry with: PSA, lipid profile, renal-hepatic profile and glycemia, and control by means of a rectal digital examination.

• To Determinate physiologic reconstitution in patients under treatment by means of total and free testosterone dosage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Santa Fe
• Collaborator: Bayer
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Patients older than 18 years old and younger than 70 years.

• To have diagnosis of erectile dysfunction by IIEF. Qualification less than 46 points and/or GAQ with Answer "NO".

• Patients with Inform consent letter signed.

• Patients without any therapy with other type of testosterone, gonadotrophines and/or PDE-5 in the previous 4 weeks of their inclusion at the study.

• Diagnosis of hypogonadism according to the criteria:

• Testosterone dosage lower than 12 nmol/L

• Free testosterone shall be below 180 pmol/L o 52 pg/mL

Exclusion Criteria:

• People less than 18 years old and older than 70 years.

• Patients with history of or with known or suspected sleep apnea.

• Patients who participate in other study protocols

• Known or suspected active systemic infection.

• Patients with HIV + and/ or known HTLV+.

• Patients with hyperprolactinemia

• Patients with known or suspected coagulopathies

• Patients with Klinefelter

• Known or suspected psychiatric illness.

• Patients who have received prior therapy with some kind of testosterone in the last 4 months or a PDE-5 inhibitor in the last month.

• Patients with contraindications for the use of PDE-5 inhibitors

• Patients having a diagnosis of erectile dysfunction but with total and/ or free testosterone levels within the physiological range.

• Patients with APE ≥ 2.5 ng/ml in younger than 60 years, or > de 3 ng/ml in older than 60 years.

• Abnormal prostate findings during the digital rectal examination (that is to say, irregularities, hard consistency when examined).

• Concomitant malignant diseases or history of prostate cancer